Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

163.58USD
22 May 2015
Change (% chg)

$-0.26 (-0.16%)
Prev Close
$163.84
Open
$163.58
Day's High
$164.57
Day's Low
$163.03
Volume
1,636,048
Avg. Vol
3,243,176
52-wk High
$173.60
52-wk Low
$113.01

AMGN.O

Chart for AMGN.O

About

Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It focuses its research and development activities on human therapeutics for in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $124,571.40
Shares Outstanding(Mil.): 760.32
Dividend: 0.79
Yield (%): 1.93

Financials

  AMGN.O Industry Sector
P/E (TTM): 22.11 37.08 39.09
EPS (TTM): 7.41 -- --
ROI: 9.40 16.21 15.55
ROE: 23.18 16.97 16.55
Search Stocks

Amgen ends partnership with AstraZeneca on psoriasis drug

- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

6:41pm EDT

UPDATE 2-Amgen ends partnership with AstraZeneca on psoriasis drug

May 22 - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

6:37pm EDT

Amgen ends collaboration with AstraZeneca on inflammation drug

May 22 - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial.

4:44pm EDT

Amgen first to win EU backing for new kind of cholesterol drug

- Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

7:27am EDT

Amgen first to win EU backing for new kind of cholesterol drug

May 22 - Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

7:23am EDT

BRIEF-EU Medicines Agency gives nod for Amgen's cholesterol drug

* Recommends approval of cholesterol drug Repatha from Amgen Inc

7:17am EDT

Amgen cholesterol drug could get EU green light this week

LONDON - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

19 May 2015

Amgen cholesterol drug could get EU green light this week

LONDON, May 19 - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

19 May 2015

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters May 14, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events. ** For

14 May 2015

UPDATE 1-Novartis 'biosimilar' drug blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

07 May 2015

Competitors

Earnings vs. Estimates

Search Stocks